



Perseus Proteomics Inc.  
Securities Code: 4882 Growth TSE  
May 13, 2022

To all stakeholders,

Notice on Booking of Non-operating Income, Non-operating Expenses,  
Extraordinary Income and Extraordinary Loss

Perseus Proteomics Inc. (The Company) announces that the non-operating income, non-operating expenses, extraordinary income and extraordinary loss were booked in the fiscal year ended March 31, 2022. The details are as follows:

1. Non-operating income

The Company has booked foreign exchange gains of 9,085 thousand yen and subsidy income of 234 thousand yen respectively, as non-operating income.

2. Non-operating expenses

The Company has booked listing expenses of 9,531 thousand yen including printing cost of prospectuses and handling fees related to public offering along with listing on Mothers Market TSE on June 22, 2021, as well as taxes and dues of 9,346 thousand yen incurred by payment for registration license tax, as non-operating expenses.

3. Extraordinary income

The Company has booked gain on reversal of share acquisition rights of 2,398 thousand yen as extraordinary income. This is because the execution conditions of the share acquisition rights will no longer be established.

4. Extraordinary loss

The Company has booked impairment loss of 117,813 thousand yen for its noncurrent assets as extraordinary loss in accordance with the Accounting Standard for Impairment of Fixed Assets.

5. Impact on financial results

The above items have been fully reflected in the “Financial Results for the Fiscal Year Ended March 31, 2022” announced today.

END